Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

188.34B

Market cap188.34B

Price-Earnings ratio

24.56

Price-Earnings ratio24.56

Dividend yield

2.76%

Dividend yield2.76%

Average volume

2.36M

Average volume2.36M

High today

$351.25

High today$351.25

Low today

$346.63

Low today$346.63

Open price

$346.63

Open price$346.63

Volume

1.98M

Volume1.98M

52 Week high

$391.29

52 Week high$391.29

52 Week low

$261.43

52 Week low$261.43

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $350.63. The company's market cap stands at 188.34B, with a P/E ratio of 24.56 and a dividend yield of 2.8%.

On 2026-04-17, Amgen(AMGN) stock moved within a range of $346.63 to $351.25. With shares now at $350.63, the stock is trading +1.2% above its intraday low and -0.2% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 1.98M, versus its average volume of 2.36M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

AMGN News

Simply Wall St 2h

Assessing Whether Amgen Still Looks Undervalued After Recent Share Price Pullback

Advertisement Context for Amgen (AMGN) after recent price moves Recent trading in Amgen (AMGN) has drawn attention after a modest 0.3% gain over the past day...

TipRanks 2d

Limited Near-Term Growth and Patent Headwinds Drive Underperform Rating on Amgen

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Sell rating on Amgen, retaining the price target of $304.00. Unlock hedge fund-level data and p...

Simply Wall St 3d

Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story

Amgen (NasdaqGS:AMGN) and Zai Lab have agreed to a global clinical trial collaboration focused on small cell lung cancer. The partnership will evaluate a combi...

Analyst ratings

51%

of 37 ratings

Buy

40.5%

Hold

51.4%

Sell

8.1%

More AMGN News

TipRanks 4d

Amgen price target raised to $400 from $390 at UBS

UBS raised the firm’s price target on Amgen (AMGN) to $400 from $390 and keeps a Buy rating on the shares. The firm adjusted targets in the pharmaceuticals and...

TipRanks 7d

Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Simply Wall St 7d

Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab

Zai Lab Limited recently announced a global clinical trial collaboration with Amgen Inc. to test Zai Lab’s DLL3-targeting antibody-drug conjugate zocilurtatug p...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.